NCT04675242View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

PHASE2CompletedINTERVENTIONAL

Enrollment

224

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

June 30, 2021

Conditions

Blepharitis

Interventions

DRUG

NCX 4251

NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily

DRUG

Placebo

Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily

Trial Locations (1)

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors

lead

Nicox Ophthalmics, Inc.

INDUSTRY

NCT04675242 - Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis | Biotech Hunter | Biotech Hunter